This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, P. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2005, p. 3558-3561, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3558-3561.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naïve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors

Patrick F. Smith,1,6* Gregory K. Robbins,2,6 Robert W. Shafer,3,6 Hulin Wu,4,6 Song Yu,2,6 Martin S. Hirsch,2,6 Thomas C. Merigan,3,6 Jeong-Gun Park,2,6 Alan Forrest,1,6 Margaret A. Fischl,5,6 Gene D. Morse,1,6 and the ACTG 384-5006 Team6

University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York,1 Harvard University, School of Medicine, Boston, Massachusetts,2 Stanford University, School of Medicine, Palo Alto, California,3 University of Rochester School of Medicine and Dentistry, Rochester, New York,4 University of Miami, School of Medicine, Miami, Florida,5 Adult AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland6

Received 2 December 2004/ Returned for modification 16 January 2005/ Accepted 5 May 2005

Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.

* Corresponding author. Mailing address: Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 219 Cooke Hall, University at Buffalo, Buffalo, NY 12460. Phone: (716) 645-2828, ext. 242. Fax: (716) 645-2886. E-mail: pfsmith{at}buffalo.edu.

Antimicrobial Agents and Chemotherapy, August 2005, p. 3558-3561, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3558-3561.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pyrko, P., Kardosh, A., Wang, W., Xiong, W., Schonthal, A. H., Chen, T. C. (2007). HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum Stress. Cancer Res. 67: 10920-10928 [Abstract] [Full Text]  
  • Nachega, J. B., Hislop, M., Dowdy, D. W., Chaisson, R. E., Regensberg, L., Maartens, G. (2007). Adherence to Nonnucleoside Reverse Transcriptase Inhibitor Based HIV Therapy and Virologic Outcomes. ANN INTERN MED 146: 564-573 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»